Search research articles
Contact Us
Filters
Showing results (151-160 of 214) with videos related to
Page
of 22
Sort By:
Pharmaceutics
|
July 24, 2020
Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs
John N Van den Anker, Susan McCune, Pieter Annaert, et al.
The Lancet. Oncology
|
April 20, 2013
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Robert J Motzer, Bernard Escudier, Piotr Tomczak, et al.
Journal of Comparative Effectiveness Research
|
September 10, 2024
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib
Imtiaz A Samjoo, Alexandra Hall, Connie Chen, et al.
The Oncologist
|
September 19, 2025
Enhancing the interpretation of real-world quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer enrolled in the POLARIS study
Gabrielle B Rocque, Joanne L Blum, Yan Ji, et al.
The Biochemical Journal
|
July 17, 2010
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Christian C Lee, Yong Jia, Nanxin Li, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 22, 2017
Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success
Gema Méndez-Lagares, Ding Lu, Connie Chen, et al.
RMD Open
|
October 31, 2020
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
Stanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
Birth Defects Research
|
February 14, 2018
Rethinking developmental toxicity testing: Evolution or revolution?
Anthony R Scialli, George Daston, Connie Chen, et al.
Breast Cancer Research and Treatment
|
August 6, 2025
Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe
Olga Oikonomidou, Mark J Beresford, Elena Galve-Calvo, et al.
Aging
|
July 7, 2021
Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways
Linjuan Huang, Ling Zhao, Jing Zhang, et al.
Page
of 22
Search research articles
Search
Showing results (151-160 of 214) with videos related to
Sort By:
Page
of 22
Pharmaceutics
|
July 24, 2020
Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs
John N Van den Anker, Susan McCune, Pieter Annaert, et al.
The Lancet. Oncology
|
April 20, 2013
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Robert J Motzer, Bernard Escudier, Piotr Tomczak, et al.
Journal of Comparative Effectiveness Research
|
September 10, 2024
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib
Imtiaz A Samjoo, Alexandra Hall, Connie Chen, et al.
The Oncologist
|
September 19, 2025
Enhancing the interpretation of real-world quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer enrolled in the POLARIS study
Gabrielle B Rocque, Joanne L Blum, Yan Ji, et al.
The Biochemical Journal
|
July 17, 2010
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Christian C Lee, Yong Jia, Nanxin Li, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
December 22, 2017
Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success
Gema Méndez-Lagares, Ding Lu, Connie Chen, et al.
RMD Open
|
October 31, 2020
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
Stanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
Birth Defects Research
|
February 14, 2018
Rethinking developmental toxicity testing: Evolution or revolution?
Anthony R Scialli, George Daston, Connie Chen, et al.
Breast Cancer Research and Treatment
|
August 6, 2025
Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe
Olga Oikonomidou, Mark J Beresford, Elena Galve-Calvo, et al.
Aging
|
July 7, 2021
Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways
Linjuan Huang, Ling Zhao, Jing Zhang, et al.
Page
of 22